HBM Holdings' HBMAT licenses drug for up to $395m

HBM Holdings Limited (HKEX: 2142) announced that HBM Alpha Therapeutics (HBMAT), an innovative biotechnology company incubated by HBM, has entered into a license and collaboration agreement for its HBM9013/HAT001 program. The agreement grants a business partner exclusive worldwide rights, excluding Greater China, to exploit pharmaceutical products related to the corticotropin-releasing hormone (CRH) targeting therapy.